Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 1, keine Gesamtzahl für „macitentan“
Suchtreffer
Begriffe & Kennungen
Yuvanci · 4.5 · Breast cancer resistance protein (BCRP) substrate drugs: In in vivo studies, macitentan 10 mg once daily did n
Eintrag öffnenYuvanci · 4.5 · CYP2C9 substrates (e.g., R-warfarin) Macitentan given as multiple doses of 10 mg once daily had no effect on e
Eintrag öffnenYuvanci · 4.5 · Ketoconazole (400 mg once daily) increased exposure to macitentan approximately 2-fold. Exposure to the active
Eintrag öffnenYuvanci · 4.5 · Oral contraceptive pill In in vivo studies, macitentan 10 mg once daily did not affect the pharmacokinetics of
Eintrag öffnenYuvanci · 4.5 · Rifampicin (600 mg daily) reduced the steady-state exposure to macitentan by 79% but did not affect the exposu
Eintrag öffnenYuvanci · 4.8 · 11 In SERAPHIN, a long-term double-blind study of macitentan in patients with PAH, hypotension was reported fo
Eintrag öffnenYuvanci · 4.8 · Hypotension has been associated with the use of ERAs including macitentan. In the double-blind period of the A
Eintrag öffnenYuvanci · 4.8 · In SERAPHIN, macitentan 10 mg monotherapy was associated with a decrease in mean leucocyte count from baseline
Eintrag öffnenYuvanci · 4.8 · In SERAPHIN, macitentan 10 mg monotherapy was associated with a decrease in mean platelet count from baseline
Eintrag öffnenYuvanci · 4.8 · In SERAPHIN, macitentan 10 mg monotherapy was associated with a mean decrease in haemoglobin of 0.69 mmol/L (1
Eintrag öffnenYuvanci · 4.8 · In SERAPHIN, the incidence of aminotransferase elevations (ALT/AST) > 3 × ULN was 3.4% on macitentan 10 mg mon
Eintrag öffnenYuvanci · 4.8 · In SERAPHIN, the incidence of oedema adverse events in the macitentan 10 mg monotherapy and placebo treatment
Eintrag öffnenYuvanci · 4.8 · Known adverse reactions for macitentan and tadalafil which have not been observed in the A DUE study, are incl
Eintrag öffnenYuvanci · 4.8 · Oedema/fluid retention has been associated with the use of ERAs including macitentan. In the double- blind per
Eintrag öffnenYuvanci · 4.8 · Table 1: Adverse reactions in patients with PAH treated with Yuvanci, macitentan and/or tadalafil System organ
Eintrag öffnenmacitentan
Eintrag öffnenmacitentan;tadalafil
Eintrag öffnen